NDAORALCAPSULE
Approved
Jan 1941
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
1
Data completeness
6/8 — Strong
DRISDOL (ergocalciferol) by Molecular Devices is clinical pharmacology the in vivo synthesis of the major biologically active metabolites of vitamin d occurs in two steps. Approved for vitamin d deficiency, secondary hyperparathyroidism. First approved in 1941.
Drug data last refreshed Yesterday · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DRISDOL (ergocalciferol) is an oral vitamin D2 provitamin compound approved in 1941 for treating vitamin D deficiency and secondary hyperparathyroidism. It works by undergoing hepatic and renal hydroxylation to form active metabolites that promote calcium and phosphorus absorption in the small intestine and mobilize these minerals from bone.
LOE Approaching
Product is in late-stage maturity with LOE approaching, indicating potential team downsizing and consolidation of commercial activities.
Mechanism of Action
CLINICAL PHARMACOLOGY The in vivo synthesis of the major biologically active metabolites of vitamin D occurs in two steps. The first hydroxylation of ergocalciferol takes place in the liver (to 25-hydroxyvitamin D) and the second in the kidneys (to 1, 25-dihydroxyvitamin D). Vitamin D metabolites…
Pharmacologic Class:
Provitamin D2 Compound
Indications (2)
Worked on DRISDOL at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.